A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults

Trial Profile

A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Meropenem
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms REPROVE; REPROVE-CAZ-AVI
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 01 Feb 2018 Results presented in an Allergan Media Release.
    • 01 Feb 2018 According to an Allergan media release, the U.S. Food and Drug Administration (FDA) has approved Allergans supplemental New Drug Application to expand the approved use of AVYCAZ to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Ha
    • 08 Oct 2017 Results presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top